Profile data is unavailable for this security.
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
- Revenue in USD (TTM)0.00
- Net income in USD-29.22m
- Incorporated2021
- Employees41.00
- LocationCalidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 794-9600
- Fax+1 (858) 794-9605
- Websitehttps://www.calidibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guardion Health Sciences Inc | 12.06m | -5.12m | 10.93m | 9.00 | -- | 3.20 | -- | 0.906 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Endexx Corp | 4.64m | 6.93m | 11.19m | -- | 1.66 | -- | 1.89 | 2.41 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| Inhibikase Therapeutics Inc | 260.50k | -19.03m | 11.20m | 8.00 | -- | 0.9749 | -- | 43.01 | -3.62 | -3.62 | 0.0489 | 1.77 | 0.0132 | -- | 13.06 | 32,562.50 | -96.49 | -66.49 | -117.79 | -85.55 | -- | -- | -7,304.76 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
| Allarity Therapeutics Inc | 0.00 | -20.42m | 11.25m | 5.00 | -- | -- | -- | -- | -4,118.49 | -4,118.49 | 0.00 | -9.35 | 0.00 | -- | -- | 0.00 | -90.14 | -- | -2,340.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.02 | -- | -- | -- |
| ABVC Biopharma Inc | 152.43k | -10.52m | 11.30m | 16.00 | -- | 1.01 | -- | 74.13 | -2.52 | -2.52 | 0.0352 | 1.06 | 0.0127 | -- | 0.3514 | 9,526.88 | -90.65 | -103.38 | -171.60 | -231.54 | -98.15 | 76.25 | -7,157.57 | -2,019.89 | -- | -3.28 | 0.153 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 11.52m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 11.53m | 64.00 | -- | -- | -- | 0.3875 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Calidi Biotherapeutics Inc | 0.00 | -29.22m | 11.59m | 41.00 | -- | -- | -- | -- | -0.6154 | -0.6154 | 0.00 | -0.1538 | 0.00 | -- | -- | 0.00 | -463.16 | -- | -- | -- | -- | -- | -- | -- | -- | -27.12 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 11.65m | -- | -- | -- | 7.69 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 11.74m | 18.00 | -- | 0.544 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Marizyme Inc | 645.81k | -65.35m | 11.86m | 11.00 | -- | -- | -- | 18.37 | -1.43 | -1.43 | 0.0142 | -0.0354 | 0.0213 | 1.56 | 8.72 | 58,710.00 | -215.30 | -59.02 | -351.53 | -64.47 | 70.87 | 70.38 | -10,118.60 | -9,435.92 | 0.0458 | -0.6565 | 1.36 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| Pioneer Green Farms Inc | 9.29k | -403.37k | 11.94m | 6.00 | -- | -- | -- | 1,285.15 | -0.0172 | -0.0172 | 0.0004 | -0.026 | 0.0154 | 0.3035 | -- | 1,548.33 | -66.94 | -- | -- | -- | 41.44 | -- | -4,341.98 | -- | 0.0106 | -30.89 | -- | -- | -- | -- | 35.41 | -- | -- | -- |
| Chemomab Therapeutics Ltd - ADR | 0.00 | -24.22m | 11.96m | 20.00 | -- | 0.0351 | -- | -- | -42.37 | -42.37 | 0.00 | 23.93 | 0.00 | -- | -- | 0.00 | -74.28 | -- | -90.33 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.39 | -- | -- | -- |
| Akari Therapeutics PLC (ADR) | 0.00 | -10.01m | 12.04m | 9.00 | -- | -- | -- | -- | -2.04 | -2.04 | 0.00 | -0.0346 | 0.00 | -- | -- | 0.00 | -110.06 | -149.95 | -1,281.64 | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 12.21m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
Data as of May 18 2024. Currency figures normalised to Calidi Biotherapeutics Inc's reporting currency: US Dollar USD
6.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Red Wave Investments LLCas of 31 Mar 2024 | 644.60k | 1.80% |
| Cable Car Capital LLCas of 31 Mar 2024 | 472.76k | 1.32% |
| Meteora Capital LLCas of 31 Mar 2024 | 249.81k | 0.70% |
| Spectrum Asset Management, Inc. (California)as of 31 Mar 2024 | 166.49k | 0.47% |
| Finepoint Capital LPas of 31 Mar 2024 | 125.00k | 0.35% |
| Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 125.00k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 107.11k | 0.30% |
| Governors Lane LPas of 31 Mar 2024 | 94.70k | 0.27% |
| Driehaus Capital Management LLCas of 31 Mar 2024 | 94.70k | 0.27% |
| CPR Investments, Inc.as of 31 Mar 2024 | 70.00k | 0.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
